Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

NEW YORK--(BUSINESS WIRE)--Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published an open letter to shareholders outlining its views of the best paths forward to maximize value. The full text of the letter is below: